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Abstract
Background: Assessment of T-cell diversity, besides giving insights about the molecular basis of
tumor antigen recognition, has clinical implications since it provides criteria for evaluating antigen-
specific T cells clinically relevant for spontaneous and vaccine-induced anti-tumor activity. Melan-A
is one of the melanoma antigens most frequently recognized by peripheral and tumor-infiltrating
lymphocytes in HLA-A2+ melanoma patients. Many clinical trials involving anti-tumor vaccination
have been conducted using modified versions of this peptide.
Methods: We conducted an in-depth characterization of 210 T-cell receptor beta chain (TRB)
clonotypes derived from T cells of HLA-A2+ melanoma patients displaying cytotoxic activity against
natural and A27L-modified Melan-A peptides. One hundred and thirteen Melan-A-specific
clonotypes from melanoma-free subjects, 199 clonotypes from T-cell clones from melanoma
patients specific for melanoma antigens other than Melan-A, and 305 clonotypes derived from T
cells of HLA-A2+ individuals showing unrelated specificities, were used as control. After sequence
analysis, performed according to the IMGT definitions, TRBV and TRBJ usage, CDR3 length and
amino acid composition were compared in the four groups of clonotypes.
Results: TRB sequences of Melan-A-specific clonotypes obtained from melanoma patients were
highly heterogeneous, but displayed a preferential usage of few TRBV and TRBJ segments.
Furthermore, they included a recurrent "public" amino acid motif (Glycine-Leucine-Glycine at
positions 110-112-113 of the CDR3) rearranged with dominant TRBV and TRBJ segments and, in
one case, associated with a full conservation of the entire TRB sequence.
Conclusion: Contrary to what observed for public anti-Melan-A T-cell receptor alpha motifs,
which had been identified in several clonotypes of both melanoma patients and healthy controls,
the unexpectedly high contribution of a public TRB motif in the recognition of a dominant
melanoma epitope in melanoma patients may provide important information about the biology of
anti-tumor T-cell responses and improve monitoring strategies of anti-tumor vaccines.
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Background
T-cell receptor (TR) plays a central role in the immune
response, interacting with peptide antigens (Ags) and with
major histocompatibility complex (MHC) molecules. TR
alpha (TRA) and beta subunits are comprised of a variable
(V) and a constant (C) amino acidic region. The TRBV
region, referred according to the ImMunoGeneTics
(IMGT) database [1], is encoded by V, diversity (D), and
joining (J) gene segments. The juxtaposition of these seg-
ments [2], the lack of precision during V(D)J gene rear-
rangement and the removal and/or addition of non-
template encoded nucleotides at V(D)J junctions [3], cre-
ate a region of hypervariability known as complementa-
rity-determining region 3 (CDR3).
Despite the potentially vast T-cell repertoire, restrictions
of TR composition, known as TR bias, are commonly
observed [4]. These TR constraints include the preferential
usage of one TRV or TRJ region without conserved CDR3,
the selection of conserved amino acids (up to five) or
'motifs' at the same CDR3 specific positions, and the
selection of clonal TR sequences with identical CDR3 [4].
The different individual responses to discrete Ags are man-
ifested in terms of personal, or "private", and shared, or
"public", motifs in the TR sequences [4]. A private TR rep-
ertoire describes a situation in which T cells of distinct
subjects responding to the same peptide-MHC complex
have no significant overlaps in their TR sequences. In con-
trast, TR repertoires are defined public when Ag-specific T
cells in several individuals use the same TR motifs, either
in the TRA or TRB chains. To date, TRA and TRB public
motifs have been described in human T-cell responses
directed against viral peptides [4], while, in the anti-
melanoma Ag response, only public TRA motifs have been
reported [5-7]. However, TRA constraints, in particular
within TRAV12-1 (previously defined Vα2 or TCRAV2.1)
T cells, were observed not only in melanoma patients [5-
7], but also in cord blood, thymocytes and PBL of non
tumor-bearing controls [5], as well as in several subjects
with vitiligo [8,9]. On the contrary, no public TRB motifs
were identified in the sequences of Melan-A-specific T
cells of melanoma patients and controls [5-8,10-19]. The
unreported identification of public TRB in anti-
melanoma Ag response may be related to the use of differ-
ent methodological approaches employed to obtain T-cell
lines or clones and to analyze CTL activity, as well as to
prepare, characterize and analyze TR sequences. Another
explanation can be the low number of patients analyzed
in different studies. To bypass these limitations we took
advantage, in the present study, of the availability of sev-
eral published and unpublished TRB sequences obtained
from a number of melanoma patients in order to study
different aspects of TRB chain structural constraints
imposed by the melanoma Ag MART1/Melan-A (hereafter
reported as Melan-A). This differentiation Ag is a mem-
brane-embedded protein of 118 amino acids expressed
both by melanocytes and melanoma cells. Among the
melanoma-associated Ags identified so far, Melan-A has
received particular attention because of its immune dom-
inance in HLA-A2+ patients. A large number of T-cell
clones generated from HLA-A2+ patients are cross-reactive
against either the natural nonamer/decamer Melan-A pep-
tide (26/27–38) or the Alanine-to-Leucine substituted
heteroclitic Melan-A A27L peptide [20,21]. Here, we iden-
tified several melanoma/HLA-A2-restricted TRB clono-
types (sequences showing different CDR3 in a given
individual), and, after the definition of a common TR
nomenclature, numbering and CDR3 designation, we
studied in details their molecular features.
Methods
The TRB sequences analyzed in this study were obtained
either from previously reported or still unpublished stud-
ies. The rationale underlying selection of the 4 groups of TR
sequences was to take into account three characteristics of
the TR clonotypes which may generate biases in the selec-
tion of CDR3 region, i.e. Melan-A specificity, HLA-restric-
tion and categories of individuals analyzed. Two hundred
and ten Melan-A-specific clonotypes [[5-7,10-18] and man-
uscript in preparation], sequenced starting from T-cell lines
or clones obtained from PBL and/or tumor-infiltrating lym-
phocytes (TIL) of melanoma patients ("Mel/M-A" group;
Table 1), were compared with 113 Melan-A-specific clono-
types ("Ctrl/M-A" group) from healthy controls and from a
subject with vitiligo [5,8,19], 199 clonotypes specific either
for melanoma Ags other than Melan-A peptide or with
undetermined specificity ("Mel/noM-A" group) obtained
from T cells of melanoma patients [22-41], and 305 clono-
types prepared from HLA-A2+ melanoma-free patients
("Ctrl/HLA-A2+" group) selected because sequenced from
T-cell lines and clones displaying CTL activity against unre-
lated Ags [42-54]. One hundred and seventy clonotypes of
the Mel/M-A group and 85 from the Ctrl/M-A group were
specific for the HLA-A2-restricted A27L-modified Melan-A
peptide and their CTL activity was evaluated using a mul-
timer-based approach [[5,6,8,12-14,17-19], and manu-
script in preparation], by competition assay [15], or by
analyzing the production of IL-2 in response to HLA-A2
Melan-A-expressing melanoma cell lines [7]. The remain-
ing 40 clonotypes derived from cells of melanoma patients
displayed CTL activity against natural Melan-A peptide, as
demonstrated by 51Cr release assay [10,11,16]. Twenty-
eight clonotypes of the Ctrl/M-A group, although specific
for Melan-A peptide, were obtained from HLA-A2-negative
healthy controls. Details on type of treatment, including
vaccination, the starting material (peripheral blood or TIL),
the experimental procedures used to obtain T-cell lines and
clones or to analyze CTL activity, as well as the methodolo-
gies for TR sequencing are specified in the references
included in Table 1. Before analysis, sequences availableJ
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Table 1: Characteristics of the TR clonotypes analyzed in this study
number of
Clono type seqa subjects/
patients 
(patients ID)b
HLA vaccination source type of 
sequenced 
cells
specificityc TRBV 
selection
references
Mel/M-A 47 90 5 
(8,22, 15, 30, 38)
A2 modified 
Melan-A
pre/postd PBL T-cell clones Melan-A* no in preparation
6 6 1 (VER) A2 no PBL T-cell clones Melan-A* no 5
26 27 3 (M199, M180, 
M138)
A2 no TIL T-cell clones Melan-A * no 6
11 11 10 (Mela01, 02, 
03, 04, 05, 06, 
10, 13, 15, 16)
A2 modified 
Melan-A CTL 
clones
pre PBL T-cell clones Melan-A*** no 7
21 7 2  ( - ) e A2 no TIL CTL lines Melan-A**** 4, 28 10
30 119 3 (1, 2, 3) A2 no PBL/TIL CTL lines Melan-A**** 7, 20, 29, 12, 
5
11
18 54 2 
(LAU 181,203)
A2 no TIL CD8-sorted 
cells
Melan-A* 27, 30 12
77 3  
(NW28, 29, 30)
A2 Melan-A, 
Tyrosinase, 
gp100
pre/post PBL CD8-sorted 
cells
Melan-A* no 13
27 50 1 (-) A2 no PBL/TIL T-cell clones Melan-A* no 14
91 0 3  
(SK9-AV, M77, 
LB373)
A2 no PBL/TIL T-cell clones Melan-A** no 15
8 9 5 (8959, LB39, 
AV, 501, 9742)
A2 no PBL/TIL T-cell clones Melan-A**** no 16
12 27 1 (LAU444) A2 modified 
Melan-A
pre/post TIL/PBL CD8-sorted 
cells
Melan-A* 6, 28 17
7 17 1 (LAU337) A2 Melan-A post PBL T-cell clones Melan-A* no 18
210 444
Ctrl/M-A 53 53 3 (HD421, 
HD009, T12)
A2 NA PBL/
Thymocytes
T-cell clones Melan-A* no 5
32 37 1 (PSA) A2 NA PBL T-cell clones Melan-A* no 8
28 28 4 (HD001, 
HD002, HD010, 
CB886)
Various A2- NA PBL CD8-sorted 
cells
Melan-A* no 19
113 118
48 1  ( - ) A 2 ,  A 2 4 p e p t i d e - p u l s e d  
DCf
post PBL/TIL - - no 22
Mel/noM-A 1 - Patient 1 A11, A32 IL-7+ 
autologous 
melanoma 
cells
pre/post PBL/TIL/DTH - - 27 23
2 2 1 (FON) A2, A29 no TIL T-cell clones autologous 
melanoma
no 24J
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4 9 1 (MZ2) Cw16 MNNG-
treated 
melanoma 
cells
pre/post PBL T-cell clones BAGE, 
MAGE1
no 25
7 140 1 (-) - no TIL/PBL/Skin - - 14, 29, 23 26
9 40 1 (-) B14 no TIL/Tissue T-cell clones/
lines/TIL
-6 2 7
25 42 6 (20113, 
20297,20254, 
20249, 20360, 
20063)
- DNP-modified 
melanoma 
cells
post TIL in 
metastases
- - no 28
6 38 1 (til 620) - no TIL T-cell colture Melan-A/
gp100
20, 19, 13 29
52 87 4 (1, 2, 5, 6) A2 no TIL, PBL, 
normal skin
- - 27, 9, 20, 29, 
28, 7
30
11 42 1 (2) autologous 
stem cells after 
CTX
pre/post PBL - - 2 31
33 2  
(BON, MAR)
A2, A25 no TIL - - 28, 2, 24 32
3 3 1 (MZ2) A1 autologous 
melanoma 
cells
PBL T-cell clones MAGE1 no 33
5 10 1 (9742) A2 no PBL/TIL T-cell clones, 
PBL-PHA
autologous 
melanoma
no 34
19 38 1 (JB) A1, A28 DNP-modified 
melanoma 
cells
post TIL - autologous 
melanoma
27 35
41 5 2  
(1200, 501)
A1, A2 no TIL bulk/CTL 
microcultures
A1/A2+ 
melanoma 
cells
no 36
22 172 3 
(1622, 1464, 
1214)
A24, 26; A3, 
11, A24
no Tissue - - 6, 27, 28, 24, 
10
37
1 1 1 (0831) A2 no TIL - - 8 38
16 100 5 
(1, 2, 3, 4, 6)
- no Tissue - - 4, 28, 25, 29 39
1 15 1 (LB256) A2 no PBL T-cell clones gp100 no 40
4 192 1 (1803) A1 no TIL bulk + cultures - 20 41
199 957
Ctrl/HLA-
A2+
41 46 15 (BD, CL, DD, 
DP, HL, JE, JM, 
JN, JW, KD, KE, 
MO, MP, NM, 
SW)
A2 NA PBL T-cell clones M58-66 (flu) 19 42
56g 606 12 (PB1, PB2, 
PB3, PB4, RA1, 
RA2, RA3, RA4, 
RA5, RA11, 
RA14, RA15)
A2 NA PBL/SFL T-cell clones/
CD8-sorted 
lines
GLC/A2 
(EBV)
2, 20, 29, 9, 
14
43
Table 1: Characteristics of the TR clonotypes analyzed in this study (Continued)J
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9 9 2 (FM, JM) A2 NA PBL T-cell lines M57-68 (flu) no 44
42 - 5 
(B, F, M, P, T)
A2 NA PBL CTL/CD8-
sorted 
population
GL9 (EBV) no 45
79 - 9 (D, F, H, K, M, 
N, P, R, S)
A2 NA PBL CTL/CD8-
sorted cells
NV9 (CMV) 45
33 43 4 (BMT, HD, RA, 
KT)
A2 NA PBL/SFL T-cell clones pp65 
(NLV/A2, 
HCMV)
no 46
59 2 3  
(003, 065, 868)
A2 NA PBL T-cell lines/
clones/CD8-
sorted cells
GAG (HIV), 
POL(HIV)
28, 5, 12 47
1 7 1 (HEU) A2 NA TIL T-cell clones lung cancer 
antigen
no 48
3 31 1 (HEU) A2 NA TIL/PBL T-cell clones alpha-actinin-
4
no 49
14 28 2 (-, 5H13) A2 NA PBL T-cell clones mHag HA-2 no 50
9 15 1 (2) A2 NA PBL CD8-sorted 
cells
19-kDa M. 
tuberculosis
no 51
6 9 1 (-) A2 NA TIL T-cell clones various tumor 
epitopes
no 52
22 9 1  ( L B 3 7 ) A 2 N A P B L C D 8 - s o r t e d  
cells
mutated malic 
enzyme
no 53
52 4 2  
(MS2, MS7)
A2 NA PBL T-cell culture TALpep no 54
305 939
a Number of sequences from which the clonotypes have been selected.
b Abbreviations: CTL: Cytotoxic T Lymphocytes; CTX: Chemotherapy; DNP: Dinitrophenyl; DTH: delayed-type hypersensitivity site: ID: Identification number; MNNG: N-methyl-N'-nitro-N-
nitrosoguanidine; NA: not applicable; Seq: sequences; SFL: synovial fluid lymphocytes; TIL: Tissue infiltrating lymphocytes.
c CTL specificity against modified Melan-A analyzed by *multimers; ** competition assay; *** production of IL-2 in response to HLA-A2 Melan-A-expressing melanoma cell lines **** or CTL 
specificity against natural Melan-A analyzed by 51Cr release assay.
d Clonotypes identified either in pre or in post vaccination.
e -: data not available.
f MAGE-4, MAGE-10, GnTV, gp100, Melan-A, FluMP, FluBNP-pulsed dendritic cells.
g Identical clonotypes are included if found in different patients.
Bold: total number of clonotypes and of sequenced TRBV chains in each group
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only in nucleotide form were translated into their amino
acidic counterparts. All sequences analyzed in this study are
supplied in the supplemental tables (additional file 1, 2, 3
and 4) showing, respectively, the clonotypes from Mel/M-
A, Ctrl/M-A, Mel/noM-A and Ctrl/HLA-A2+ groups. In
order to obtain uniformed information, TRBV gene family
and CDR3 amino acid positions were named and num-
bered according to the IMGT indications http://
imgt.cines.fr[55].
Statistical analysis
To analyze TRBV or TRBJ segment usage, the 95% confi-
dence intervals of the respective proportions were calcu-
lated. "Preferentially used" were defined those segments
whose lower limit of the respective 95% confidence inter-
val was higher than the mean percentage of TRBV or TRBJ
transcripts usage, obtained by arbitrarily hypothesizing a
uniform distribution of all segments. When proportions
were compared, Fisher's exact test was employed, while
the differences between the means of CDR3 length distri-
butions in the four groups of clonotypes were evaluated
by Kruskal-Wallis test and Dunn's post-hoc test. Results
were considered significant for p < 0.05.
Results
Preferential TRBV and TRBJ usage in HLA-A2/Melan-A 
restricted response in melanoma patients
We first investigated whether clonotypes identified in
HLA-A2+ melanoma patients with CTL specificity against
Melan-A (Mel/M-A group) had a preferential usage of par-
TRB segments usage Figure 1
TRB segments usage. TRBV (A) and TRBJ (B) segments usage and CDR3 length (C) in clonotypes prepared from Melan-A-
specific CTL lines and/or clones of melanoma patients (Mel/M-A), clonotypes from Melan-A-specific CTL of healthy controls 
and of a patient with vitiligo (Ctrl/M-A), clonotypes of melanoma patients specific for melanoma Ags other than Melan-A or 
with unknown specificity (Mel/noM-A), clonotypes from HLA-A2+ subjects derived from T lymphocytes specific for Ags unre-
lated to melanoma (Ctrl/HLA-A2+). The sequences analyzed here are those reported in Table 1. As indicated in Table 1, in 
some papers a pre-selection of cells bearing some specific TRBV segments was done before sequencing. * TRBV and TRBJ 
chains preferentially used within clonotype groups. The TRB nomenclature used throughout the paper is that of Lefranc et al 
[1]; the nomenclature reported in parenthesis is that of Arden et al [49]. (aa): amino acids.
*
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ticular TRBV chains and whether these preferential TRBV
were also predominantly utilized in the control (Ctrl/M-
A, Mel/noM-A and Ctrl/HLA-A2+ groups) clonotypes. As
shown in Figure 1A, multiple transcripts covering the
majority of the TRBV families were observed in the 4
groups of clonotypes, although some TRBV segments were
preferentially used. In particular, while TRBV6 and
TRBV27 were highly represented in all groups of clono-
types, TRBV4 was overrepresented in response to
melanoma Ags but not to unrelated Ags, TRBV19 was pref-
erentially used in clones of HLA-A2+ control individuals,
and TRBV28 appeared to be preferentially selected only by
Melan-A-specific CTL. TRBV usage comparison among the
4 groups suggested that the proportion of clonotypes
Amino acid frequency Figure 2
Amino acid frequency. Amino acid frequency in the entire IMGT-defined CDR3 (A) and in the position 110, 112 and 113 of 
the CDR3 (B) in the indicated groups of sequences.
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using TRBV27 chains was higher in Mel/M-A, Ctrl/M-A
and Mel/noM-A sequences compared to Ctrl/HLA-A2+
clonotypes (p = 0.03; p = 0.004; p < 0.001), while TRBV28
was significantly more frequent in Mel/M-A clonotypes
than in Mel/noM-A and Ctrl/HLA-A2+ groups (p = 0.001
and p < 0.001).
Among Mel/M-A clonotypes there was a high number of
clonotypes bearing the TRBJ2-1, TRBJ2-7 and TRBJ1-5 seg-
ments (Figure 1B). However, the first two TRBJ chains,
however, were highly utilized also in other groups of
clonotypes (Figure 1B), and had also been frequently
observed among peripheral blood T-cells from healthy
individuals [56].
The mean CDR3 length was highly similar (p = NS) in
Mel/M-A, Ctrl/M-A and Mel/noM-A groups (mean ± SD:
12.37 ± 1.29, 12.32 ± 1.43 and 12.35 ± 1.71, respectively),
but significantly lower in Ctrl/HLA-A2+ clonotypes
(11.95 ± 1.50) in respect to Mel/M-A (p < 0.01) and Mel/
noM-A sequences (p < 0.05). Furthermore, the majority of
Mel/M-A and Ctrl/M-A CDR3 were 12 amino acid long
(32.9% and 31.9% respectively), while most of CDR3 of
Mel/noM-A and Ctrl/HLA-A2+ sequences were 13- and
11-amino acid-long, respectively (Figure 1C).
Collectively, the present analysis demonstrated that in
melanoma patients there is a biased T-cell response to
Melan-A, which is characterized by TR clonotypes using
preferentially TRBV28 and TRBJ1-5 segments and contain-
ing a 12-amino acid-long CDR3.
Public TRB CDR3 motif within HLA-A2/Melan-A-restricted 
clonotypes of melanoma patients
The amino acid composition of TRB hypervariable regions
of Melan-A-specific CTL from melanoma patients were
subsequently analyzed in detail. Serine, Glycine, Alanine
and Glutamine were by far the most frequently used resi-
dues in the IMGT-defined CDR3, and were almost equally
represented in all groups of analyzed sequences (Figure
2A). However, while Alanine, Serine, and Glutamine were
abundantly present because of their occurrence at posi-
Public motifs in Melan-A-specific clonotypes Figure 3
Public motifs in Melan-A-specific clonotypes. Aminoacidic composition and sequence alignments of public CDR3 of 
Melan-A-specific clonotypes found in melanoma patients. aPBL: peripheral blood lymphocytes; bTIL: tumor infiltrating lym-
phocytes; cNA: ID not available; dm: modified Melan-A A27L; eClonotype 4 was obtained from one T- clone was obtained 
before and one after vaccination; fX: amino acid not available; gn: natural Melan-A. In dark gray: amino acids identical to the 
consensus sequences; in light gray: other preferentially used amino acids at the given position; in bold: amino acids belonging to 
N-D-N region; in the boxes: hydrophilic amino acids at position 109 and 114.Journal of Translational Medicine 2009, 7:21 http://www.translational-medicine.com/content/7/1/21
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tions 105, 106, 107 and 114 in the majority of canonical
TRBV and TRBJ chains, Glycine, as reported for murine
[57] and human sequences [56], was clearly predominant
in the region created by N-D-N recombination events.
Furthermore, in the N-D-N region of Mel/M-A and Ctrl/
M-A sequences there was an increased Leucine usage (Fig-
ure 2A), and Glycine and Leucine were overrepresented at
CDR3 positions 110, 112 and 113 (Figure 2B). Moreover,
the overall percentage of non-polar amino acids at these
CDR3 positions in the clonotypes carrying 12-amino acid-
long CDR3s, which were the most commonly represented
among the Melan-A-specific T-cell clones, was signifi-
cantly higher in the Mel/M-A group (75%) compared to
Ctrl/M-A (62%, p = 0.017), Mel/M-A (52%, p < 0.001)
and Ctrl/HLA-A2+ (38%, p < 0.001) groups. This indi-
cates that non-polar amino acids may be important for
Melan-A-peptide-TR interaction. Furthermore, we found a
public clonotype identified in two laboratories from cells
of two melanoma patients: one was sequenced in our lab-
oratory starting from a T-cell clone (ID 16) obtained from
patient 22 [manuscript in preparation], the other from a
T-cell clone (ID 27) obtained in the laboratory of Traut-
mann  et al [6] employing melanoma-infiltrating lym-
phocytes of patient M180 (Figure 3). Both sequences
Table 2: Nucleotide composition of available N-D-N regions of public Melan-A-specific clonotypes of melanoma patients
Clone ID 3' V region N1 P D region N2 5' J region TRBV TRBJ References
D/a GCCAGCAGTTTA.. ....CAGGGG.. CTGGGG .......CAGCCCCAGCA
T
28 1–5 14
30 GCCTGGAGTGT ...ACAGGGG.. CTGGGG .....TATGGCTACACC 30 1–2 in preparation
50B,55 GCCAGCAGCTT... CACTGGGCT ......GGGG.. .......CAGCCCCAGCA
T
71 – 5 1 4
17 GCCAGCA....... TCTGGG ....CAGGG... CTCGGG .......CAGCCCCAGCA
T
28 1–5 in preparation
814S1 XXXXXXA....a CGAAT ....CAGGGG.. CTCGGG .......CAGCCCCAGXX
X
30 1–5 12
82899S32 XXXXXX..... GGGCAAAT .......GGGGC TCGGG .......CAGCCCCAGXX
X
30 1–5 12
A/5 AGTGCTAG... TGTGCC .......GGGGC TCGGG .......CAGCCCCAGCA
T
20 1–5 14
25 GCCAGCAG...... ACA ...ACAGGGG.. TTGGG .........TTCACCCCT
CCAC
28 1–6 in preparation
814S2 XXXXXXAG... CCCGGT .....AGGG... TTGGG ......TCAGCCCCAGXX
X
30 1–5 12
82899S26 XXXXXXAGT.. C C ....CAGGGGGC TCGG ......TCAGCCCCAGXX
X
30 1–5 12
42 GCCAGCAGT..... G T ...ACAGGGG.. CTCGG ......TCAGCCCCAGCA
T
28 1–5 in preparation
D/b GCCAGTAGTAT... ..GACAGGG... CTAGGG .......CAGCCCCAGCA
T
19 1–5 14
6 AGTGC....... GCCCGAT ...ACAGGG... CTTGGC .......CAGCCCCAGCA
T
20 1–5 in preparation
4 GCCAGCAG...... ATACCA GGGAC....... TAGGA .......CAGCCCCAGCA
T
28 1–5 in preparation
39 GCCTGGAGTGT C C ....CAGGG... CTAGG ......TCAGCCCCAGCA
T
30 1–5 in preparation
NA XXXXXXAGT.. CAT ....CAGGG... ATTGGG ....CTATGGCTACXXX 30 1–2 12
16 GCCAGCA....... CCCT ..GACAGGG... CTTGGA .......CAGCCCCAGCA
T
28 1–5 in preparation
6E4 GCCAGCAGTTT... TCT C GGG......... TTGGG ....CACTGAAGCTTTC 28 1-1 18
40 GCCAGCAGTTTA.. ....CAGGG... TTGGGG .....ACTGAAGCTTTC 28 1-1 in preparation
B/22 GCCAGCAGT..... C A ...ACAGGG... TTTGGG ......TCAGCCCCAGCA
T
28 1–5 14
41 GCCAGCAG...... CCA ...ACAGGGG.. CTCGG ....CACTGAAGCTTTC 28 1-1 in preparation
B/9 GCCAGCAGTTT... TCA GGGAC....... TCGG ......TCAGCCCCAGCA
T
28 1–5 14
aNucleotides not availableJournal of Translational Medicine 2009, 7:21 http://www.translational-medicine.com/content/7/1/21
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contained identical 12-amino acid-long CDR3s, created
by the joining of TRBV28 and TRBJ1-5 segments and con-
taining a Glycine-Leucine-Glycine stretch at positions
110-112-113 of the CDR3. This motif was recurrent
among other sequences derived from several patients,
since it was found in 27 additional clonotypes sequenced
in different laboratories and obtained from 15 melanoma
patients. This peculiar motif rearranged only with mem-
bers of TRBJ1 cluster, because 19 out of 29 clonotypes
were joined with TRBJ1-5 segments, 7 with TRBJ1-1, 2
with TRBJ1-2 and one with TRBJ1-6 (Figure 3). TRBV
usage was also restricted in these clonotypes since 16 of
them were TRBV28, 7 were TRBV30 and 2 were TRBV20.
The recurrent motif was found in Melan-A-specific CTL
isolated from PBL and from tumor sites of HLA-A2+
melanoma patients, independently of the stage of disease
and of the methodological approaches used for T-cell
cloning. The same motif was identified in two Melan-A T-
cell clones derived from cells of healthy donors [5,19], but
not in the remaining 504 clonotypes sequenced from T-
cell lines or clones with specificity for other Ags. Similarly,
the Glycine-Leucine-Glycine motif at position 110-112-
113 was absent in the 219 clonotypes identified analyzing
353 sequences randomly obtained from CD8+ lym-
phocytes of healthy subjects (data not shown). Further-
more, no common motifs were found when Melan-A-
specific sequences of melanoma patients were compared
using particular BV or BVBJ combinations. Of clinical rel-
evance, the Glycine-Leucine-Glycine motif was detected in
lymphocytes obtained from untreated patients, represent-
ing spontaneous anti-tumor responses, as well as from
patients having undergone vaccination with the natural or
modified peptides (Figure 3). Interestingly, one clonotype
sequenced in our laboratory (ID 4) was detected both in
samples prepared before and after the vaccination [58].
Furthermore, all but one clonotype containing the Gly-
cine-Leucine-Glycine motif were sequenced from T-cell
clones whose specificity was identified using modified
Melan-A peptide/multimers. The specificity of the remain-
ing clone for natural Melan-A peptide was established by
the analysis of the ability of Melan-A-transfected COS-7
cells to stimulate IFN-γ release. This last clonotype (ID
1E2), identified by Cole et al [10], bore TRBV28 and
TRBJ1-1 chains and differed only by the amino acid at
position 109 (Figure 3) from ID 57, ID CTL01 and ID 6E4
clonotypes [6,7,18], which were sequenced starting from
3 melanoma patients. Furthermore, the same motif was
present, at slightly different positions of the CDR3, in 7
other Melan-A-specific clonotypes [5,7,10,19], but never
in non-Melan-A clonotypes. While the Glycine-Leucine-
Glycine stretch is composed exclusively by non-polar or
frankly hydrophobic amino acids, all the amino acids at
position 114 and several of those at position 109 were
hydrophilic (Figure 3). Finally, we looked for very similar
sequences at the same CDR3 positions because it is con-
ceivable that these sequences adopt equivalent structures
in the recognition complex. We found a Glycine-Valine-
Glycine stretch in 8 clonotypes, 5 of which were identified
in melanoma patients [[4,12,14,30] and manuscript in
preparation] and 3 in controls [3,5].
Since previous studies focusing on the analysis of shared
TR amino acid sequences in humans did not address the
extent to which TRB nucleotides are shared among public
amino acid stretches, we identified the N-D-N regions of
the 22 available nucleotide sequences of clonotypes with
Glycine-Leucine-Glycine at position 110, 112 and 113. As
summarized in Table 2, all N-D-N regions were different,
with the only exception of those of ID D/a and ID 30
sequences, in which, however, the Adenine at the extreme
3'V region must be ascribed to the TRBV segment in clone
ID D/a and to the D region in clone ID 30. Finally, the
alignment of the 22 nucleotide sequences with the TRBV,
TRBJ and TRBD germline gene segments allowed us to cal-
culate the germline contribution and the number of
nucleotide deletions (the so-called "nibbling") and addi-
tions during the VDJ recombination process. The exonu-
cleolytic nibbling was highly heterogeneous: at 3' V end
varied from 0 to 7 nucleotides, at 5' J end ranged from 4
to 9, at 3' D from 0 to 9 and at 5' D from 0 to 7. Similarly,
N-addition was highly different at both sites ranging from
0 to 9 nucleotides at N1 and from 0 to 6 at N2 position.
Finally, also TRBD region length is diverse since it varies
from 3 to 8 nucleotides.
Discussion
T-cells recognize peptide Ags in the context of MHC mol-
ecules through their TR, and during chronic infections,
autoimmunity and alloreactivity a preferential use of par-
ticular TRA or TRB regions has been observed [4]. There-
fore much effort has been put into the characterization
also of tumor Ag-specific TRs. Several data demonstrated
a major role of TRAV than TRBV chains in TR-Ag recogni-
tion, due to the higher number of contacts of this chain
with peptides [59], and, accordingly, a preferential usage
of a TRAV chain has been observed in Melan-A-specific T
cells from melanoma or vitiligo  patients and healthy
donors [5-9]. However, this has not been considered a
result of TR repertoire narrowing due to affinity focusing
during Ag-driven immune responses, but to reflect a struc-
tural constraint already present in the pre-immune TR rep-
ertoire [5,9]. Differently from TRAV, the TRBV repertoire
of Melan-A-specific T lymphocytes appears to be large and
diverse in terms of clonal composition and TRBV region
usage, as multiple clonotypic transcripts, covering the
majority of the TRBV families, have been identified in
HLA-A2+ patients [5-7,14,17]. Conversely, other authors
reported that the recognition of melanoma Ags involved
the use of T lymphocytes bearing specific TRBV chains,
such TRBV5, TRBV9, TRBV19, TRBV27, and TRBV28Journal of Translational Medicine 2009, 7:21 http://www.translational-medicine.com/content/7/1/21
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[16,18,23,30,35]. The different results are likely due to
intrinsic limitations imposed by the limited number of
patients analyzed and by the fact that the mature TR rep-
ertoire is influenced not only by the coding potential of
TR VDJ regions, but also by the immunological history of
the individuals. To clarify this issue, we analyzed several
HLA-A2/Melan-A-specific clonotypes derived from 40
melanoma patients and we compared their features with
those found in 103 other individuals including 8 subjects
of Ctrl/M-A group, 36 of Mel/noM-A group and 59 of Ctrl/
HLA-A2+ group. This comparative analysis indicated that
T cells reacting with melanoma Ags utilize preferentially
TRBV27 chain, but this segment is also predominant in
clonotypes with unrelated specificity derived from HLA-
A2+ individuals. On the contrary, TRBV28 chain is signif-
icantly more represented in HLA-A2+/Melan-A-specific T-
cell clones obtained from melanoma patients and con-
trols. It is of note that TRBV27 and TRBV28 chains (previ-
ously defined TCRBV14S1 and TCRBV13S1, respectively)
were expressed at very low percentage when PBL of
healthy individuals were analyzed by cytofluorimetry
using a panel of TRBV subfamily-specific mAbs covering
about 65% of TR-expressing cells [60]. Although we can-
not exclude that anti-TRBV27 and anti-TRBV28 mAbs may
not recognize well these TRBV chains, the overexpression
of these segments in the clonotypes that we have analyzed
strongly suggests that these TRBV segments are important
for melanoma Ag recognition, with TRBV28 being prefer-
entially involved in the interaction between TR and
Melan-A.
Looking in depth at the peculiar features of TR-Melan-A
interaction, we found a biased utilization of TRBJ1-5 seg-
ment and a 3-amino acid-long Glycine-Leucine-Glycine
public motif occurring in several clonotypes of melanoma
patients. Further biases were the frequent association of
this public motif with TRBV28 and TRBJ1-5 segments and
the lack of rearrangement with members of TRBJ2 cluster.
The finding of this public motif demonstrates that the dis-
crepancy between the anti-viral and anti-melanoma Ag
responses is only apparent and supports our hypothesis
that the lack of common TRB constraints among patients
analyzed in different studies [5-8,10-18] is likely due to
the paucity of individuals studied and to the diverse tech-
nical approaches employed for the sequence analysis.
Indeed, Mandruzzato et al [14] have previously identified
the Glycine-Leucine-Glycine stretch, but they could not
appreciate the frequency of this feature since they studied
a single melanoma patient. Clones carrying recurrent
motifs were present at low frequency in each patient,
exception made for two patients from whom 9 and 28
clones with the same Glycine-Leucine-Glycine-containing
TR were isolated [12,18], while during viral infections,
public clonotypes are very frequent not only within the
population, but are also sequenced in a large number in
the same patient [4,43-46]. This is not surprising since
most of these studies were carried out in the context of
chronic, most likely lifelong, viral infections, i.e. EBV
infection, where exposure to Ags is continuous and a
selective pressure on T cells remains constantly high.
There is not a general rule that could account for the
occurrence of public T-cell responses. Some public TRB
motifs have been made from near-germline recombina-
tion events, involving only few nucleotides deletion from
V, D and J germline and no or minimal random nucle-
otide additions [61,62] but the extent of exonucleolytic
nibbling and the substantial number of nucleotide addi-
tions in the public anti-Melan-A TR stretch exclude that its
public nature is generated by near-germline rearrange-
ments.
Looking at the biochemical structure of the public motif
identified, one may speculate that the Glycine-Leucine-
Glycine stretch positioned in the central region of the
CDR3, which is surrounded by hydrophilic residues, can
favour the interaction with the antigenic Melan-A peptide,
which has a similar central Glycine-Isoleucine-Glycine
motif, with the large non polar side chain of the Isoleu-
cine protruding extensively from the molecular surface
[63]. The relevance of this and of other structural affinities
in the two sequences, such as the potential interactions
between the hydrophilic residues flanking their central
positions, might be assessed with more confidence when
further data on the recently crystallized TR-Melan-A-MHC
complex [64] will be available, and the spatial relation-
ships between Melan-A and CDR3 amino acids will
became clearer.
Conclusion
The finding of a conserved amino acid motif in the CDR3,
together with the selective use of certain TRBJ and TRBV
segments, indicates an important role of the TRB chain in
fine-tuning TR affinity of Melan-A-specific T cells of
melanoma patients and argues against the hypothesis that
high affinity TRs against self-Ags, like Melan-A, are
removed during selection in the thymus or, alternatively,
by tumor-induced deletion of dominant TR clonotypes
[65].
Further studies are needed to elucidate the clinical rele-
vance of these melanoma-associated clones, which were
found not only in T-cell clones isolated from PBL but also
from tumor sites, thus suggesting some lymph-node hom-
ing properties of the T cells bearing the public motif.
However, whatever the function of these clonotypes is, the
occurrence of this public CDR3 sequence may have impli-
cations for the tracking of tumor Ag-specific T cells in dif-
ferent clinical settings. In particular, sensitive molecular
approaches targeting TRBV28+TRBJ1-5+ cells bearing Gly-Journal of Translational Medicine 2009, 7:21 http://www.translational-medicine.com/content/7/1/21
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cine-Leucine-Glycine motif could be designed to
immune-monitor Melan-A-specific responses in
melanoma patients and to investigate whether the pres-
ence of this specific motif can provide prognostic infor-
mation, contributing to the design of efficient anti-
melanoma vaccines.
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